Establishment and Characterization of Meningioma Patient-derived Organoids

September 6, 2023 updated by: George KC Wong, Chinese University of Hong Kong
In this study, meningioma organoids will be established from patients' tissues and the characterization of the organoid will be performed.

Study Overview

Status

Completed

Conditions

Detailed Description

Aims and Hypothesis to be tested:

The investigators hypothesized that the derived organoid should have a similar morphological and genetic mutation signatures to the patient primary tissue.

Study period: 1 year for patient recruitment and organoid generation from patient tumor

Study population: 30

Study samples:

Patient's meningioma tumor sample are collected from patients with surgical needs. Sample collected are used for organoid culture. Morphological and genetic characteristics will be compared between the patient tumor sample and the corresponding derived organoids

Primary outcome measures:

Whole exome sequencing data of patient tumor tissue and patients-derived organoids

Study Type

Observational

Enrollment (Actual)

20

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Hong Kong
      • Hong Kong, Hong Kong
        • Department of Surgery, The Chinese University of Hong Kong

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Sampling Method

Non-Probability Sample

Study Population

Patients with meningioma admitted to Prince Wales Hospitals neurosurgical services

Description

Inclusion Criteria:

  1. Adult patients (aged >18 years) with meningioma
  2. Admission into Prince Wales hospitals neurosurgical services
  3. Patients with surgical needs of meningioma removal

Exclusion Criteria:

1. Patients (or next-of-kin as appropriate) refuse to participate into the study

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Whole exome sequencing data
Time Frame: 7 days
DNA extracted from patient tumor tissue and patients-derived organoids will be perform whole exome sequencing for genetic characterization.
7 days

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Immunostaining
Time Frame: 7 days
H&E staining and meningioma markers immunostaining
7 days

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Chinese University of Hong Kong

Investigators

  • Principal Investigator: George KC Wong, Chinese University of Hong Kong

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

May 23, 2020

Primary Completion (Actual)

August 31, 2023

Study Completion (Actual)

August 31, 2023

Study Registration Dates

First Submitted

July 16, 2020

First Submitted That Met QC Criteria

July 16, 2020

First Posted (Actual)

July 21, 2020

Study Record Updates

Last Update Posted (Actual)

September 7, 2023

Last Update Submitted That Met QC Criteria

September 6, 2023

Last Verified

September 1, 2023

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • GWMO01

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Meningioma

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Azerbaijan

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe